Search Results (821)
Click the Why column to see why an item matched the search.
| Match | Type | Why |
|---|
| Anticoagulant options in atrial fibrillation: When new treatments become standard practice. | Academic Article |
Why?
|
| Rivaroxaban: a novel oral anticoagulant for the prevention and treatment of several thrombosis-mediated conditions. | Academic Article |
Why?
|
| Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum. | Academic Article |
Why?
|
| Drug Interactions With Non-Vitamin K Oral Anticoagulants. | Academic Article |
Why?
|
| Emerging anticoagulants for venous thromboembolism prevention. | Academic Article |
Why?
|
| New developments in pediatric venous thromboembolism and anticoagulation, including the target-specific oral anticoagulants. | Academic Article |
Why?
|
| Novel oral anticoagulants and reversal agents: Considerations for clinical development. | Academic Article |
Why?
|
| Select Drug-Drug Interactions With Direct?Oral Anticoagulants: JACC Review Topic of the Week. | Academic Article |
Why?
|
| The New Direct-Acting Oral Anticoagulants Need to be Monitored! | Academic Article |
Why?
|
| Berkowitz, Scott | Person |
Why?
|
| Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. | Academic Article |
Why?
|
| Nonadherence with INR monitoring and anticoagulant complications. | Academic Article |
Why?
|
| Trujillo, Toby | Person |
Why?
|
| Current concepts of anticoagulant therapy in pregnancy. | Academic Article |
Why?
|
| Adherence to and persistence with direct oral anticoagulant therapy among patients with new onset venous thromboembolism receiving extended anticoagulant therapy and followed by a centralized anticoagulation service. | Academic Article |
Why?
|